Pyrazinamide
- Generic Name
- Pyrazinamide
- Brand Names
- Rifater, Tebrazid
- Drug Type
- Small Molecule
- Chemical Formula
- C5H5N3O
- CAS Number
- 98-96-4
- Unique Ingredient Identifier
- 2KNI5N06TI
- Background
A pyrazine that is used therapeutically as an antitubercular agent.
- Indication
For the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents.
- Associated Conditions
- Active Tuberculosis, Pulmonary Tuberculosis (TB)
Evaluating Celecoxib Activity in Mycobacterium Tuberculosis: A Whole Blood Bactericidal Activity Study in Healthy Volunteers
- Conditions
- Tuberculosis
- Interventions
- First Posted Date
- 2015-11-11
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 18
- Registration Number
- NCT02602509
- Locations
- 🇸🇬
National University Hospital, Singapore, Singapore
A Randomised Trial to Evaluate Toxicity and Efficacy of 1200mg and 1800mg Rifampicin for Pulmonary Tuberculosis
- Conditions
- Pulmonary Tuberculosis
- Interventions
- First Posted Date
- 2015-10-21
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- St George's, University of London
- Target Recruit Count
- 672
- Registration Number
- NCT02581527
- Locations
- 🇺🇬
Epicentre, Mbarara, Uganda
🇵🇪Hospital Nacional Dos de Mayo, Lima, Peru
🇳🇵GENETUP, National Anti-TB Association, Kathmandu, Nepal
Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis
- Conditions
- Tuberculosis
- Interventions
- Dietary Supplement: Pyridoxine
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 60
- Registration Number
- NCT02563327
- Locations
- 🇺🇬
Mulago Hospital, Kampala, Uganda
Fermented Soybean Supplementation Among Active Pulmonary Tuberculosis Patients With Standard Therapy in Indonesia
- Conditions
- Motor ActivityBody Weight ChangesPulmonary Tuberculosis
- Interventions
- Dietary Supplement: Fermented soybean
- First Posted Date
- 2015-09-18
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- University of Giessen
- Target Recruit Count
- 147
- Registration Number
- NCT02554318
The Optimal Duration of Preoperative Anti-tuberculosis Treatment of Spinal Tuberculosis
- Conditions
- Tuberculosis, Spinal
- Interventions
- First Posted Date
- 2015-06-23
- Last Posted Date
- 2015-06-23
- Lead Sponsor
- Beijing Chest Hospital
- Target Recruit Count
- 400
- Registration Number
- NCT02477852
- Locations
- 🇨🇳
Beijing chest hospital, Beijing, Beijing, China
PK Study of Anti-TB Drugs
- Conditions
- Tuberculosis
- Interventions
- First Posted Date
- 2015-05-29
- Last Posted Date
- 2018-10-03
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 61
- Registration Number
- NCT02457208
- Locations
- 🇹🇭
Shoklo Malaria Research Unit, Mae Sot, Tak, Thailand
An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis
- Conditions
- TuberculosisMultidrug Resistant TuberculosisExtensively-drug Resistant Tuberculosis
- Interventions
- First Posted Date
- 2015-05-27
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- University of Cape Town
- Target Recruit Count
- 154
- Registration Number
- NCT02454205
- Locations
- 🇿🇦
Brooklyn Chest Hospital, Cape Town, Western Cape, South Africa
The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB
- Conditions
- MDR-TB
- Interventions
- Drug: Regimen A locally-used WHO-approved MDR-TB regimen (2011 guideline)
- First Posted Date
- 2015-04-06
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- IUATLD, Inc
- Target Recruit Count
- 588
- Registration Number
- NCT02409290
- Locations
- 🇪🇹
Armauer Hanssen Research Institute, Addis Ababa, Ethiopia
🇪🇹St. Peter's Tuberculosis Specializes Hospital, Addis Ababa, Ethiopia
🇬🇪JSC National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia
Shortening Treatment by Advancing Novel Drugs
- Conditions
- Tuberculosis, Pulmonary, Multi Drug-resistantTuberculosis, Pulmonary, Drug Sensitive
- Interventions
- Drug: HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination)Drug: HR (rifampicin plus isoniazid combination tablets)
- First Posted Date
- 2015-01-21
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 284
- Registration Number
- NCT02342886
- Locations
- 🇹🇿
Kilimanjaro National Institute for Medical Research, Mwanza, Tanzania
🇿🇦TASK, Bellville, Cape Town, South Africa
🇺🇬Uganda CWRU Research Collaboration, Kampala, Uganda
Assessing PA-824 for Tuberculosis (the APT Trial)
- Conditions
- Pulmonary Tuberculosis
- Interventions
- First Posted Date
- 2014-10-06
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 157
- Registration Number
- NCT02256696
- Locations
- 🇿🇦
University of Cape Town Lung Institute, Cape Town, South Africa
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.